Redeye comments on FluoGuide’s Q3 2024 report, following its recent business update on FG001’s planned development in head and neck cancer. We judge the company faces various high-impact clinical and business development catalysts in 2025e. We adapt our estimates and valuation to the company’s recently announced plans. Our view of the investment case remains essentially unchanged.
